<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02769793</url>
  </required_header>
  <id_info>
    <org_study_id>16-2015-52</org_study_id>
    <nct_id>NCT02769793</nct_id>
  </id_info>
  <brief_title>Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in PD Patients With Delayed ON</brief_title>
  <official_title>Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in Parkinson's Disease Patients With Delayed ON: a Multicenter Randomized Open-label Cross-over Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SMG-SNU Boramae Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether levodopa/benserazide dispersible is
      effective in the adjunctive treatment of Parkinson's disease (PD) patients with delayed ON.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Delayed ON is one of the motor complications of advanced PD patients that effect of
      anti-parkinsonian medication is delayed more than 40 minutes after intake. In the most severe
      cases, the effect does not appear even until next medication schedule, so called &quot;No ON&quot;
      status. It is important to manage delayed ON properly because it can interfere motor
      functions and quality of life of PD patients.

      Levodopa/benserazide dispersible can be absorbed rapidly in the intestine, so theoretically
      it can break the poor response to conventional treatment of PD patients with delayed ON.
      However, this has not been proven by clinical trials till now.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the time to ON after first morning dose using 3-day PD diary</measure>
    <time_frame>4 weeks</time_frame>
    <description>A specialized 3-day PD diary will be distributed to the patients 3 days prior to each visit. This diary will evaluate the latency of ON after intake of the study medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the The Unified Parkinson Disease Rating Scale (UPDRS)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the The Unified Dyskinesia Rating Scale (UDyskRS)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the The Schwab &amp; England Activity of daily living scale (SEADL)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the The Parkinson Disease Questionnaire-39 (PDQ-39)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Patient global improvement (PGI)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Clinician global improvement (CGI)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the K-Minimental status examination (K-MMSE)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Total ON time, total OFF time using 3-day PD diary</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Levodopa dispersible</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levodopa dispersible 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levodopa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levodopa 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa dispersible</intervention_name>
    <description>Levodopa dispersible 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)</description>
    <arm_group_label>Levodopa dispersible</arm_group_label>
    <other_name>Madopar dispersible</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa</intervention_name>
    <description>Levodopa 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)</description>
    <arm_group_label>Levodopa</arm_group_label>
    <other_name>Madopar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients between 31 and 80 years

          -  Parkinson disease (PD) was diagnosed by United Kingdom Parkinson disease brain bank
             criteria

          -  Patients receiving stable Levodopa treatment at least 2 weeks prior to baseline visit

          -  Delayed ON was confirmed by a specialized PD diary that records change in motor
             symptoms 90 minute after the first morning dose. Delayed ON is defined as delay of
             more than 40 minutes after the first morning dose for resolution of OFF state or
             experience of no ON state at least 1 per week.

        Exclusion Criteria:

          -  Existence of cognitive decline hard to participate in the clinical trial or
             K-Minimental Status Exam score 24 or less

          -  Any contraindication of blood sampling

          -  Subjects with clinically significant psychiatric illness

          -  Subjects with a cancer or severe medical illness

          -  Lactating, pregnant, or possible pregnant

          -  History of malignant melanoma

          -  Subjects with narrow-angle glaucoma

          -  Subjects with hypersensitivity to levodopa or benserazide

          -  Subjects treated with non-selective monoamine oxidase (MAO)-B inhibitors

          -  Subjects with peptic ulcer, colitis, or gastrointestinal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>31 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jee-Young Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SMG-SNU Boramae Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jee-Young Lee, MD, PhD</last_name>
    <email>wieber77@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chae Won Shin, MD, MSc</last_name>
    <email>chroma0202@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinwhan Cho, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jee-Young Lee, M.D.</last_name>
      <phone>82-2-870-2476</phone>
      <email>wieber77@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jee-Young Lee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2016</study_first_submitted>
  <study_first_submitted_qc>May 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2016</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jee-Young Lee</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Benserazide</mesh_term>
    <mesh_term>Benserazide, levodopa drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

